Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solriamfetol to Promote Wakefulness in Patients With Primary Gliomas
NCT03868943Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2021
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of solriamfetol in glioma and glioblastoma (GBM), sponsored by Wake Forest University Health Sciences. Primary endpoint: Proportion With Grade 3 or Higher Adverse Events. Started Jan 2021; status: terminated.
02
Drugs
solriamfetol
03
Conditions
gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT03868943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03868943.